Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
First-in-human single-ascending-dose study of Lu AF95245 in healthy men
NL-OMON48207Active, not recruiting
- Sponsor
- Lundbeck
- Start
- Jan 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, double-blind trial of Lu AF95245 in mental disorder and neurological diseases (3 arms), sponsored by Lundbeck. Primary endpoints: Number of participants with treatment-emergent adverse events, AUC(0-inf) of Lu AF95245 and 8 more. Started Jan 2020; status: active, not recruiting.
02
Drugs
Lu AF95245
03
Conditions
mental disorderneurological diseases
Beyond the preview
Go deeper on NL-OMON48207.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON48207.